NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.0030
0.00 (0.00%)
At close: Nov 20, 2026
NKGen Biotech Employees
NKGen Biotech had 26 employees as of December 31, 2024. The number of employees decreased by 37 or 58.73% compared to the previous year. That makes NKGen Biotech the 37,572nd largest employer in the world and 5,286th in the United States.
Employees
26
Change (1Y)
-37
Growth (1Y)
-58.73%
Revenue / Employee
n/a
Profits / Employee
-$905,923
Market Cap
391.81K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 26 | -37 | -58.73% |
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aditxt | 26 |
| Altamira Therapeutics | 11 |
| CERo Therapeutics Holdings | 8 |
| Mosaic ImmunoEngineering | 7 |
| Ampio Pharmaceuticals | 6 |
| Actavia Life Sciences | 1 |
NKGen Biotech News
- 5 days ago - NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer's Treatment Troculeucel at CTAD 2026 - GlobeNewsWire
- 13 days ago - NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer's Disease at CTAD 2026 - GlobeNewsWire
- 2 months ago - NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum - GlobeNewsWire
- 2 months ago - NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 - GlobeNewsWire
- 4 months ago - NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions - GlobeNewsWire
- 6 months ago - NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment - GlobeNewsWire
- 7 months ago - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - GlobeNewsWire
- 8 months ago - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ - GlobeNewsWire